Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2, and no study content or critical details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedRemoved the site-wide notice about government funding lapse and potential delays in processing. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check32 days agoChange DetectedThe updated page preserves the same study details and sections (overview, eligibility, interventions, outcomes, and contacts). Only layout and visual elements appear updated, with no changes to core content.SummaryDifference0.4%

- Check61 days agoChange DetectedSummary of changes: added a government funding notice with current operating status guidance and updated version to v3.2.0; removed the old version label v3.1.0.SummaryDifference5%

- Check68 days agoChange Detected- Updated revision from v3.0.2 to v3.1.0. - Added phone contact: 886-3-668-4800 ext 3201.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.3%

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.